Press Releases

February 15, 2024

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors

PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.

January 4, 2024

Revolutionizing Spatial Biology: PredxBio to Showcase their Cutting-Edge Innovations at JP Morgan Healthcare Week

PredxBio, a pioneering force in spatial biology, today announces its participation in the DigiMed Showcase taking place during JP Morgan Healthcare Week. B. Dusty Majumdar, PhD, the CEO of PredxBio, will present the company’s revolutionary solutions live on Monday, January 08, 2024, at 9:45 AM (PT). The presentation will delve into PredxBio’s cutting-edge solutions, showcasing how the company is shaping the future of cancer care through spatially intelligent biology, utilizing unbiased Spatial Analytics and Explainable AI.

June 14, 2023

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors, Strengthening Expertise in Oncology and Precision Medicine

PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression, is pleased to announce the addition of Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, to its Board of Directors.

June 7, 2023

PredxBio Strengthens Leadership Team with Appointment of Brad Spitz as Chief Commercial Officer

PredxBio, the leading company in Spatial Biology and Explainable AI for predicting the progression of disease has announced the appointment of Brad Spitz, MBA, as its Chief Commercial Officer. In this role, Brad will drive the company’s commercial growth strategy, lead global sales and business development efforts, and further expand PredxBio’s presence in the biopharma industry.

April 17, 2023

PredxBio is bending the survival curve for immunotherapy cancer patients with spatially intelligent biology at AACR 2023

PredxBio (formerly SpIntellx) announces that it will attend the 2023 Annual Meeting of American Association for Cancer Research in Orlando, April 15-19, Booth #974 and Poster #5445 to present their explainable AI-powered unbiased spatial analytics platform, that seamlessly integrates multimodal data to unravel the hidden circuitries of the tumor microenvironment and reveal the complex network biology of the cancer…

April 4, 2023

SpIntellx Rebrands as PredxBio to Unlock Spatial Biology Insights with Explainable AI

SpIntellx, the leader in Spatial Biology leveraging Explainable AI for predicting the progression of disease, announced today its rebranding as PredxBio (pronounced, “pre-dix-bio”). The PredxBio platform is designed to empower drug discovery, translation, and clinical trials, initially focusing on immuno-oncology space…

August 18, 2022

PredxBio and iCura Diagnostics Partner to Expand Access to Advanced Spatial Analytics and Explainable AI Products for Pathology and Oncology Research

PredxBio, Inc., a leader in spatially intelligent biology and iCura Diagnostics, a leading contract research organization focused on capitalizing multiomic data to accelerate end-to-end clinical workflow solutions and biomarker discovery, have announced a partnership to transform precision oncology through unlocking the power of genomic, proteomics, and transcriptomic data using advanced spatial analytics…

JULY 18, 2022

PredxBio and Inspirata Announce New Technical Partnership and Integration to Expand Access to Next Generation Explainable AI Software for Breast Biopsies

PredxBio, Inc., and Inspirata have announced that they will collaborate to integrate the PredxBio HistoMapr-Breast™ platform and Inspirata’s Dynamyx® software into one seamless solution. HistoMapr-Breast is the one and only computational pathology software that taps the power of explainable artificial intelligence (xAI) for healthcare providers to diagnose, prognosticate and treat breast cancer more efficiently and accurately…

MAY 16, 2022

PredxBio Appoints Industry Leader B. Dusty Majumdar, Ph.D. as Chief Executive Officer to Spearhead the Next Phase of Growth

B. Dusty Majumdar, Ph.D. has been appointed as the Chief Executive Officer (CEO) of PredxBio, Inc., a precision pathology company whose mission is focused on dramatically improving patient outcomes fueled by proprietary unbiased spatial analytics and explainable AI. Dr. Majumdar, is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across diagnostic imaging, oncology, multi-omics,…

APRIL 05, 2022

PredxBio is ushering a new era of unbiased spatial analytics and explainable AI in precision pathology at AACR 2022

PredxBio, Inc. created the new era of precision pathology to dramatically improve patient outcomes by leveraging proprietary unbiased spatial analytics and explainable AI. PredxBio’s precision pathology solutions have the potential to unlock a plethora of new applications in medicine and research by answering the fundamental question “Why?” , thus revealing the underlying patient-specific disease network biology across each stage of the drug development, diagnostics, and treatment pipelines…

MARCH 18, 2022

PredxBio announces the new era of precision pathology at USCAP 2022

PredxBio, Inc. created the new era of precision pathology to dramatically improve patient outcomes by leveraging proprietary unbiased spatial analytics and explainable AI that answers the question “Why?” to reveal the underlying patient-specific disease network biology, across each stage of the drug development, diagnostic and treatment pipelines. PredxBio offers software as a service (SaaS) for precision pathology applications harnessing unbiased spatial analytics and explainable AI including: accelerated drug discovery for identifying novel targets, biomarkers and “invisible” cell types; optimized clinical trials for precision patient stratification;…

JUNE 14, 2021

Meet the 7 life science startups of AlphaLab Health’s inaugural accelerator cohort

Seven promising life science startups started off 2020 with a shot of support from two of the region’s health and economic development-minded orgs. Launched in September 2020, AlphaLab Health is an initiative of Innovation Works, which also runs the AlphaLab and AlphaLab Gear accelerator programs, and Allegheny Health Network. Those selected for the program’s cohorts receive early-stage funding of up to $100,000, access to mentorship and clinical expertise through AlphaLab’s network,…

JULY 20, 2020

PredxBio and CellNetix Collaborate to Validate HistoMapr-Breast™, an Explainable AI Software Platform Featuring Advanced Spatial Analytics to Provide Intelligent Guides for Pathology Laboratories

PredxBio, Inc., and CellNetix Pathology & Laboratories have announced that they will collaborate to validate the PredxBio HistoMapr-Breast™ Platform, which taps the power of explainable artificial intelligence (xAI) for healthcare providers to diagnose and treat breast cancer more efficiently and accurately…

DECEMBER 17, 2019

Innovations in Artificial Intelligence, Cloud, Blockchain, and Analytics, 2019: Advances in AI, Blockchain, and Business Intelligence - ResearchAndMarkets.com

This edition of IT, Computing and Communications (ITCC) TechVision Opportunity Engine (TOE) provides a snapshot of the emerging ICT led innovations in artificial intelligence, machine learning, cloud, and analytics. This issue focuses on the application of information and communication technologies in alleviating the challenges faced across industry sectors in areas such as banking, oil & gas, healthcare, life sciences, and industrial sectors…